Back to search

France· FR:60891060

TETRALYSAL 300 mg, gélule

A lymecycline product containing lymécycline, registered in France by GALDERMA INTERNATIONAL, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC J01AA04

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedTETRALYSAL 300 mg, géluleATCJ01AA04REGISTER NO.FR:60891060PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Lymecycline is registered in 12 of 19 countries.

Countries holding a registration under ATC J01AA04 (lymecycline), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose

Lymecycline · ATC J01AA04

12 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lymecycline costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Lymecycline · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

  • CH Switzerland$2.52
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
LYMÉCYCLINE
Manufacturer
GALDERMA INTERNATIONAL
Country
France (FR)
ATC code
J01AA04
ATC class
Lymecycline
Defined daily dose
0.6 g, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400936759800
    film(s) thermosoudé(s) aluminium polyéthylène de 28 gélule(s)
    EUR 5.97

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

53 interactions on record for lymecycline.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Lymecycline · interactions on record

53 records

53 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Lymecycline in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lymecycline products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Cyclopel
  • Belgium · Lymecycline (Entsprechend Tetracyclin-Base) Brown & Burk, Lymecycline (Équivalent À Tétracycline Base) Brown & Burk
  • Denmark · Lymecyclin " Brown & Burk ", Lymecyclin Actavis
  • Finland · Lymecycline Brown & Burk, Lymecycline Ratiopharm
  • United Kingdom (Northern Ireland) · Lymecycline, Lymecycline Actavis
  • Hungary · Tetralysal
  • Ireland · Lycimor, Rimicorim
  • Iceland · Lymecycline Actavis
  • Malta · Tetralysal
  • Norway · Lymecyclin Actavis, Lymecycline Brown & Burk
  • Poland · Tetralysal
  • Portugal · Limeciclina Atral
  • Sweden · Lymecycline Actavis, Lymecycline Glenmark

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ed0925f3-0722-48e5-8c55-e90b0ab9be2b
GET /v1/drugs/ed0925f3-0722-48e5-8c55-e90b0ab9be2b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "60891060",
  "date_amm": "2005-02-03",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "LYMÉCYCLINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": "Warning disponibilité",
  "forme_pharmaceutique": "gélule",
  "voies_administration": "orale",
  "etat_commercialisation": "Non commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about lymecycline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.